The epitalon and thymalin stack traces to a 2003 study that gave Epithalamin, a pineal extract, not epitalon. What was studied, course totals and units.
Epitalon and thymalin are sold together as a longevity pairing, one named for the pineal gland and one for the thymus. The pairing has a real origin: a research institute in St. Petersburg studied a pineal preparation and a thymus preparation side by side and published a long follow-up of the two in elderly people. What that study gave was not what the vials sold today contain. This page reports what was combined, what was not, what the registered and circulating figures are, and the units for each.
Each compound's own record is on epithalon dosage and thymalin dosage. Other combinations and what is on record for them are listed in the stacks section.
What the 2003 study combined
The paper is titled "Peptides of pineal gland and thymus prolong human life". Its abstract describes 266 "elderly and older persons" observed for 6 to 8 years by two institutes, in St. Petersburg and Kiev, with the preparations applied for the first 2 to 3 years. The preparations were Thymalin, described as thymic, and Epithalamin, described as pineal.
| Group in the abstract |
Mortality compared with control |
| Thymalin |
Lower by a factor of 2.0–2.1 |
| Epithalamin |
Lower by a factor of 1.6–1.8 |
| Thymalin plus Epithalamin |
Lower by a factor of 2.5 |
| Separate group, both annually for 6 years |
Lower by a factor of 4.1 |
Three things about this table matter for anyone reading it as support for a stack. The abstract states no dose for either preparation. It describes a clinical assessment against a control group, with no mention of randomisation or blinding. And the report comes from the institute that developed both preparations. A Russian-language report of the same study appeared a year earlier (Advances in Gerontology 2002, PMID 12577695) with the same figures.
Extract and tetrapeptide are different things
Epithalamin is a mixture extracted from cattle pineal glands. Epitalon is the single tetrapeptide Ala-Glu-Asp-Gly, designed afterwards from the extract's amino acid composition; a 2002 review by the same first author describes that design step and says epitalon "reproduces the effects of Epithalamin" in animals (Khavinson, Neuro Endocrinology Letters 2002, PMID 12374906). That is the developer's claim about animal work. It is not a human trial of the tetrapeptide with Thymalin, and there is none:
| PubMed records naming epitalon or epithalon together with thymalin (2026-11-11) |
Kind |
| Avolio et al., Int J Mol Sci 2022 (PMID 35408963) |
Five peptides tested on a human cell line in culture |
| Adv Gerontol 2002 (PMID 12096446) |
Rat tissue culture |
| Khavinson 2002 (PMID 12374906) |
Review |
| Adv Gerontol 2010 (PMID 21510076) |
Review |
| Adv Gerontol 2011 (PMID 21809618) |
Review |
Five records, none of them a study in people. For the extract the count is larger — 12 records name Epithalamin with Thymalin — and that is where the 2003 follow-up sits.
Thymalin has the same split in a different form. The registered Russian product is an extract of calf thymus, 10 mg per vial. Whether a research-market vial labelled thymalin holds that extract or a synthetic peptide is not something its label establishes.
The one registry record
ClinicalTrials.gov held no record for thymalin on 2026-11-11 and one for epitalon. NCT07888595, registered by a sponsor named Frontiers in Bioscience Research Institute and Aging, with one site in Irvine, California, was first posted on 2026-10-22: an early phase 1, single-group study of 48 people, enrolling by invitation. Epitalon appears in it as one of five small peptides (with GHK-Cu, AHK-Cu, PGP and CLV) in a water-based serum applied to skin at about 1 to 3 mg/mL, with untreated skin as the comparison. The record is reported here as it appears. It does not inject epitalon, does not include Thymalin and has posted no results.
| Preparation |
Source |
Daily amount |
Days |
Course total |
10 mg vials |
| Thymalin |
Russian registration (Vidal entry, recorded 2026-10-10) |
5–20 mg, intramuscular |
3–10 |
30–100 mg |
3–10 |
| Thymalin |
One randomised COVID-19 trial (PMID 33575961, recorded 2026-10-10) |
10 mg, intramuscular |
5 |
50 mg |
5 |
| Epitalon |
Vendor figures (this site's chart, 2026-09-18) |
5 mg |
20 |
100 mg |
10 |
| Epitalon |
Vendor figures (same) |
10 mg |
10 |
100 mg |
10 |
| Epitalon |
Largest published human daily amount (recorded 2026-09-20) |
0.5 mg, sublingual |
20 |
10 mg |
1 |
The two circulating epitalon schedules are the same 100 mg arranged two ways. That total is ten times the 10 mg of the largest published human course, which was given under the tongue, not injected. Thymalin's circulating figures follow its registration. No row in this table is a combined schedule, because no source states one.
Both in syringe units
On a U-100 syringe, units = amount ÷ concentration × 100. Both are sold as 10 mg vials.
| Vial and water |
Concentration |
5 mg |
10 mg |
20 mg |
| 10 mg + 1 mL |
10 mg/mL |
50 |
100 |
two vials |
| 10 mg + 2 mL |
5 mg/mL |
100 |
200 (two syringes) |
two vials |
The rows apply to either compound. The epithalon calculator and the thymalin calculator work any other volume. The registered Thymalin route is intramuscular; the circulating epitalon figures are described as subcutaneous, a route no published human epitalon study used.
What is not established
No human study has given synthetic epitalon with Thymalin, at any dose. The 2003 mortality figures belong to two extracts, come from an abstract with no dose and no description of randomisation, and were reported by the preparations' developers. Neither compound is approved in the United States or the European Union. Nothing on this page is a dose or a suggestion to use either or both; Medibact's epithalon guide and its thymalin guide cover the molecules and their evidence.
Sources and dates
Opened 2026-11-11: the PubMed abstracts of Khavinson and Morozov, Neuro Endocrinol Lett 2003 (PMID 14523363), its Russian-language report (PMID 12577695), Khavinson 2002 (PMID 12374906), Avolio et al., 2022 (PMID 35408963) and the 2010 review (PMID 21510076); PubMed searches for epitalon or epithalon with thymalin (5, each record's type read), Epithalamin with thymalin (12), epitalon or epithalon (144) and thymalin (293); ClinicalTrials.gov v2 API searches for thymalin (0), epithalamin (0) and epitalon (1), and the full record of NCT07888595. The Thymalin registration, the COVID-19 trial, the vendor figures and the sublingual study are as recorded on this site's thymalin and epithalon pages with the dates shown. Course totals, vial counts and units are arithmetic by this site. Corrections go to the contact page.